Showing 1,041 - 1,060 results of 104,281 for search '(( 2 fold decrease ) OR ( 5 ((point decrease) OR (((a decrease) OR (mean decrease)))) ))', query time: 1.47s Refine Results
  1. 1041

    All data points from Fig 6. by Sara Hijazi (21656615)

    Published 2025
    “…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”
  2. 1042
  3. 1043
  4. 1044
  5. 1045

    Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

    Published 2017
    “…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
  6. 1046
  7. 1047

    WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression. by Ayana E. Morales (17756335)

    Published 2024
    “…Corresponding densitometry analysis is noted as protein fold expression compared to GAPDH for WT1, p<0.001(***), vFLIP(ns), LANA p<0.05(*), pAKT p<0.05(*), and BCL2 p <0.05(*) using two-sided, unpaired student t-tests. …”
  8. 1048
  9. 1049
  10. 1050
  11. 1051
  12. 1052

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  13. 1053
  14. 1054

    Signatures of the Protein Folding Pathway in Two-Dimensional Ultraviolet Spectroscopy by Jun Jiang (149215)

    Published 2015
    “…The complexity of signals decreases as the conformational entropy decreases in the course of the folding process. …”
  15. 1055

    The novel <i>carboxylesterase 1</i> variant c.662A>G may decrease the bioactivation of oseltamivir in humans by Jaeseong Oh (3947381)

    Published 2017
    “…A novel <i>CES1</i> c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease CES1 enzymatic activity in an <i>in silico</i> analysis. …”
  16. 1056
  17. 1057
  18. 1058

    Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study by Jilles M. Fermont (3746068)

    Published 2020
    “…In total, 291 of 714 individuals experienced 762 hospitalised AECOPD during five-year follow up. Poorer performance of SPPB was associated with both higher rate (IRR 1.08 per 1 point decrease, 95% CI 1.01 to 1.14) and increased length of stay (IRR 1.18 per 1 point decrease, 95% CI 1.10 to 1.27) for hospitalised AECOPD. …”
  19. 1059
  20. 1060